AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

BioMidwest

How Perceptions of High Drug Prices Do Not Necessarily Match Reality

The U.S. public apparently believes that drug prices are too high. At the same time, they seem largely opposed to government efforts to control health care costs, alternately supportive and non-supportive of efforts to eliminate the Affordable Care Act, better known as Obamacare.

December 5, 2018

5 min read

Mark Terry

Policy

FDA Approves NIH-Funded Genetic Database, Issues Draft Guidance on NASH

The FDA is often publishing draft guidelines and asking for expert feedback on that guidance. It’s been a busy week in this regard, with several areas of healthcare and drug development and manufacturing being covered by the agency. Here’s a look.

December 5, 2018

3 min read

Mark Terry

Business

BioSpace Feature: A Look at Miracle Drug Humira’s Journey to Proven Efficacy

“Humira is an anti-TNF monoclonal antibody that currently treats Crohn’s disease, rheumatoid arthritis, ulcerative colitis, hidradenitis suppurativa, psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis and uveitis,” quotes Humira developer AbbVie’s website. Those, plus other unlisted ailments, total at 15 conditions treated by only one drug.

December 4, 2018

4 min read

Elizabeth Glasure

Biotech Beach

Upcoming Highlights from the 60th Annual American Society of Hematology Meeting

The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.

November 30, 2018

3 min read

Mark Terry

Policy

Many Pharma Directors Also Hold Leadership Roles in Healthcare Nonprofits

Many of these directors do not publicly disclose their affiliation with the pharma companies in their nonprofit biographies, report shows.

November 30, 2018

3 min read

Alex Keown

Business

New Report Expresses Optimism Over Current State of Alzheimer’s Drug Development

Noting that from 1998 to 2017 there have been about 146 failed shots at developing drugs for Alzheimer’s disease, PhRMA released a report on the state of the industry. This would not lead most people to think there are many reasons to be optimistic about Alzheimer’s disease research, but the report does believe there are good reasons to be.

November 30, 2018

3 min read

Mark Terry

FDA

AbbVie and Genentech Snag Accelerated Approval for Venclexta in AML

AbbVie could be eyeing another potential billion dollars of annual revenue following the accelerated approval of Venclexta for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older or who cannot tolerate intensive chemotherapy.

November 26, 2018

2 min read

Alex Keown

Business

One Busy Week for AbbVie: Hepatitis C, Fibroids, Alzheimer’s & Parkinson’s, and Generic Criticism

AbbVie presented additional data from two Phase III clinical trials in women with uterine fibroids. In a big news week for the company, what else is AbbVie up to?

November 15, 2018

4 min read

Mark Terry

Business

AbbVie’s Mavyret Demonstrates Sky-High Cure Rates in Hepatitis C

Chicago-based AbbVie just announced new data for its Mavyret (glecaprevir/pibrentasvir), a pan-genotypic treatment for chronic HCV in treatment-naive patients with compensated cirrhosis.

November 14, 2018

3 min read

Mark Terry

JOBS